Portage Biotech Inc. (PRTG)

[goodspot]

This is the proposal according to Salva RX.Looks to me like a split in shares for shareholders and US citizens will not be able to do anything with their stock for 6 months. https://www.bloomberg.com/press-releases/2018-08-20/pharmaventures-advises-salvarx-group-plc-on-the-acquisition-of-salvarx-ltd-by-portage-biotech-inc

[goodspot]

Heres the latest i found on Portage https://www.bloomberg.com/press-releases/2018-08-20/pharmaventures-advises-salvarx-group-plc-on-the-acquisition-of-salvarx-ltd-by-portage-biotech-inc

[mauiguy2]

Yes, you certainly seem to be correct regarding the halt. I just hadn't seen any official word of it when I made my previous post.

This latest move by management should prove to be VERY interesting!!!

[goodspot]

there is a halt in trading due to the new possible acquisition. And i only think it will be beneficial for PTGEF holders./

[mauiguy2]

I don't think there was a halt in trading. Rather, it was simply a day with no volume. I think the market was taken it all in without making quick buy/sell decisions.

SalvaRx's shares nearly doubled. So, they're happy.

Like I said earlier, the PTGEF group is a proven winner. If they think this acquisition is a great deal to enhance shareholder value, I support this move.

[bbhuey]

Does anyone have an opinion on the halt in trading and the conditional acquisition of salvia of UK for the issuance of 767 Million shares of ptgef for salvia will affect our pps? So far ptgef has not traded

[mauiguy2]

They've already invested in a few other companies.

Here's my take and why I remain very upbeat regarding PTGEF's prospects. This same ownership group was very successful in its BHVN investment. If they've done it once, they can do it again. I'd much rather put my personal investment into a company that's already experienced a big win than with an investment group that's never had a winner.

[bbhuey]

Looks like the stock has gone dormant.
Anybody have any idea of what their next move is or idea of what they are working on that will become a near term catalyst

[mauiguy2]

There's currently a 500,000 share bid of .14 on PTEGF. That's no small potatoes for a stock that was recently trading in the .08's and .09's with not nearly the same volume as it does these days. It goes without saying that there is a strong demand to own shares.

[clayton1]

Seems like there something brewing....

[mauiguy2]

I feel the same. Volume has been high.

[clayton1]

Have a feeling something going to happen very soon....

[mauiguy2]

PTGEF has been a great hold. It seems to be gearing up once again. I like their plan. BHVN remains a part of my portfolio also.

[Nightroads]

Portage invests in Stimunity S.A, a Paris-based cancer immunotherapy companyPR Newswire

PR Newswire•February 28, 2018
TORONTO, Feb. 28, 2018 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") (Canadian Securities Exchange: PBT.U, OTC Markets : PTGEF), is pleased to announce that it has made an investment in Stimunity, SAS ("Stimunity"), a Paris-based immuno-oncology company. Portage's will invest up to €2,000,000 subject to the successful completion of milestones. Stimunity will use the proceeds of this seed round to fund the preclinical development of its lead product, a potent biologic enhancer of the STING pathway that activates the immune system against tumor cells.

"The discovery of cancer checkpoint immunotherapy has made huge improvements in the treatment of multiple cancer types, particularly in highly inflamed tumors. However, typically 50% or more of patients won't respond and require better treatment options," said Dr. Ian B. Walters, a board member of Portage. "Scientists are searching for safe and effective agents to augment checkpoint activity, and drive long term responses in resistant tumors."

Stimunity's lead candidate is a Virus-Like Particle ("VLP") encapsulating the natural agonist of STING; these VLPs will fuse with immune cells and induce a potent T-cell response against tumor cells that are poorly immunogenic. The lead program is now at the early phase of preclinical validation. Nicolas Manel PhD, Stimunity's co-founder and the co-inventor of its technology is very confident, saying, "Early in vivo data shows that our approach synergizes with immune checkpoint therapies and leads to a potent therapeutic effect on distant tumors which is what most of patients need."

"The collaboration between Stimunity and Portage opens another chapter for Portage, providing the company with a program advancing into human testing. Stimunity's technology has the potential to stimulate the tumor microenvironment and promote an immune response in a safer and more potent fashion than other STING agonists. We believe these properties will enable Stimunity's STING agonists to become an important adjuvant to checkpoint inhibitors in non-immunogenic tumor types," said Greg Bailey, Chairman of Portage.

Stimunity's seed round will help the company complete its preclinical package and advance the manufacturing process used to create its virus-like particles to pharmaceutical grade. Dr. Ian B. Walters will chair Stimunity's Board of Directors. "We are very excited by our collaboration with Portage; it not only brings significant investment to the table, but also provides strong expertise in immuno-oncology and clinical development. We are happy to welcome Ian onto our board." said Sylvain Carlioz, co-founder and CEO of Stimunity.

About Stimunity

Stimunity is an early-stage research and development company focused on the development of STING agonists in cancer. The technology, licensed from Institut Curie, Inserm, and the University of Oxford, is based on a unique biologic approach which encapsulates endogenous STING-activating molecules in a Virus-Like Particle (VLP). Stimunity's drug has the potential to be best-in-class, activating the innate immune system and enhancing T-cell response against tumor cells with low immunogenicity.

More information at:

http://stimunity.com
[e-mail]


About Portage

Portage is engaged in supporting the discovery and development of pharmaceutical and biotech products through clinical "proof of concept" with a focus on areas of unmet clinical need. Following proof of concept, Portage will seek to sell or license these products to large pharmaceutical or biotechnology companies for further development and commercialization. Portage has an interest in novel targeted therapies, stem cell therapies, and new indications for older marketed products that have been found to have novel patentable characteristics that bring new value to patients.

Forward-Looking Statements
This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release, are forward-looking statements. The use of certain words, including the "believe", "could", "expect" and "will" and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans and objectives disclosed in the forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements, including uncertainties relating to the future clinical success. Additional important factors to be considered in connection with forward-looking statements are described in the "Risk Factors" section of the Company's quarterly financials and Management Discussion and Analysis and annual Report in Form 20-F filed on SEDAR and EDGAR. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

[PNW_Ryan]

anyone else see the jump in Portage's PPS to +/- $0.40 after hours last night?

[Nightroads]

Portage 's PPL forms a joint venture with University of Glasgow to develop new peptide therapeutics
PR Newswire PR Newswire•February 2, 2018
TORONTO, Feb. 2, 2018 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTCQB: PTGEF, Canadian Stock Exchange: PBT.U) is pleased to announce that its wholly owned subsidiary, Portage Pharmaceuticals Ltd. ("PPL'), has formed a new joint venture company, Portage Glasgow Limited ("PGL"), incorporated in Scotland, to develop more effectively-targeted drugs to treat chronic conditions including cancer.

PPL will hold controlling interest in PGL.

Portage Pharmaceuticals is providing an undisclosed funding to the new business along with a limited license to its CellPorter™ peptide delivery technology.

The University of Glasgow is providing therapeutic peptides developed through the research of Prof. George Baillie and access to a therapeutic peptide discovery platform.

PGL will focus on the commercialisation of new therapies aimed at disrupting protein-protein interactions (PPI) in disease pathways which give therapeutic benefit. Candidate peptides and PPI targets have already been identified from existing research at the University.

Dr Frank W. Marcoux is a founding Director and the CEO of PGL. He currently serves as the Chief Executive Officer and Chief Scientific Officer of Portage Pharmaceuticals Ltd. and has over 25 years of drug development experience in a variety of senior management roles at Pfizer and Parke-Davis, culminating with an eight year tenure as Vice President, Pfizer Global Research and Development.

Professor George Baillie is the academic founding director of the company. He is the Professor of Molecular Pharmacology at the University of Glasgow's Institute of Cardiovascular and Medical Sciences and worked for 15 years on publically and privately-funded research in phosphodiesterase enzymes and protein-protein interactions.

Dr. Declan Doogan, CEO of Portage commented, "'This is a great example of a collaboration between commercial drug developers and academic researchers who have the potential to deliver truly cutting edge much needed treatments to patients world wide. I am excited to be associated with this Glasgow based enterprise. "

Dr. Gregory Bailey, Chairman of Portage commented. "Our joint venture with Glasgow is not only part of the evolution of PPL, but also the beginning of the next chapter for Portage Biotech. We are looking for compelling products or companies that our team can add value to. Portage Biotech will be pathology agnostic and will evaluate new companies opportunistically".

Please also refer to the News Release dated January 31, 2018 by the University of Glasgow which can be found at www.glasgow.ac.uk.

About Portage

Portage is engaged in the discovery and development of pharmaceutical and biotech products through clinical "proof of concept" with a focus on areas of unmet clinical need. Following proof of concept, Portage will seek to sell or license these products to large pharmaceutical or biotechnology companies for further development and commercialization. Portage has an interest in novel targeted therapies, stem cell therapies, and new indications for older marketed products that have been found to have novel patentable characteristics that bring new value to patients.

Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release, are forward-looking statements. The use of certain words, including the "believe", "could", "expect" and "will" and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans and objectives disclosed in the forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements, including uncertainties relating to the future clinical success. Additional important factors to be considered in connection with forward-looking statements are described in the "Risk Factors" section of the Company's quarterly financials and Management Discussion and Analysis and annual Report in Form 20-F filed on SEDAR and EDGAR. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

[TP-Money]

Can anyone help me understand the tax consequences of the PTGEF dividend?

Do I just pay a tax on the BHVN shares I received, or do I pay tax on the profits I make on the BHVN/PTGEF shares combined?

[Khan Punjabi]

When will we know the future of Portage Biotech? When Kam Shah sings. Kam Shah chief financial officer Portage Biotech. But is it Kam Shah??? It doesn't matter, Enjoy !!!

?

?

[mauiguy2]

I couldn't be more pleased with the way things are shaping up. BHVN has been flying since the dividend and PTGEF has been bouncing back. I have been very impressed with PTGEF management and will continue to hold onto my shares. I added at .07.

[Khan Punjabi]

Honoring tradition with innovation equal success. Naan bread is nothing but a Pita without a Tandoori oven.

[Khan Punjabi]

I agree that it is highly possible Portage will invest in a conjunctive medication for chronic kidney disease patients. Cannabis derived medications for puritis and loss of appitite and other effects of chronic kidney disease could be considered. This would go well with Sentians present studies and Portage would have less restriction being out of Ontario Canada than some other US companies.

[brooklyn13]

I like PTGEF a lot, their business model seems unique and I've been buying since the dividend.

There are 265M shares outstanding of PTGEF, if you divide that by 46, the result is about 5.76M, meaning that PTGEF still owns about 500K shares of BHVN unless I'm missing something.

[MufasaBreath]

Portage said that they were going to sell the Biohaven shares. Using the money for day to day expenses and future biotechs. I'm riding my BHVN for the hopeful run up to P3 and then maybe sell half before the news. Increased my holdings in Portage 4 fold during the drop. Wouldn't be surprised if they made an investment in the cannabis arena. Just my .02

[brooklyn13]

If this share payout dividend means that the company cashed in all of their shares of BHVN, then something fundamentally changed. I have no idea.

[shmully]

I'm confused by the negative PTGEF posts. What the hell happened to all the positive talk about PTGEF pre-dividend. All the stuff in the pipeline? All the exceptional management? Blah, blah, blah! Did anything fundamentally change with regards to PTGEF to warrant the negative sentiments, except a dividend to shareholders, which to me is positive?

[TP-Money]

I received my BHVN shares this morning. I got the correct amount.

[serious38]

Though you got a BHVN shares, I don't see how anyone will profit much if they sell PTGEF shares at this price. I think the best thing is to buy low at this price, that is if you believe in Mgmt. & company. IMO

[willlbone]

Canadian Nickle soon.

[brooklyn13]

No, not right, 1/4 was the cutoff date in the US, 1/3 in Canada. I received the correct number of BHVN shares this morning.

[rob64]

I think there is a reverse stock split coming with PTGEF
i only received 120 shares of BHVN FOR 7500 SHARES OF PTGEF AND WAS THE RECORD DATE TO BUY PTGEF JAN 5 TO BUY MORE? .I THINK I SHOULD HAVE RECEIVED MORE,EVERY 46 SHARES OF PTGEF SHOULD RECEIED 1 OF BHVN THATS 163 SHARES, IS THIS RIGHT?

[rob64]

I think there is a reverse stop split coming with PTGEF

[serious38]

No Stock Div. today, and stock price hits new 52 week low. Strange!

[serious38]

No Stock Div. today, and stock price hits new 52 week low. Strange!

[shmully]

To both of us!

[brooklyn13]

That's why they play the games, good luck to you.

[shmully]

Me either. Can take 2 days. Don't forget the holiday yesterday.

[shmully]

I called it. Where are all the new investors that can get in at 7 cents, with Portage being talked up positively at every turn? Something's up?

[shmully]

So glad to see you have taken a walk to the "dark side"...lol. That was my initial sentiment, the whole thing is a "mystery" to me. I get the dividend, blah, blah, blah and I'm grateful for it. That being said, where are the new investors who can get in at 7 cents, with Portage being talked up at every turn? I let your initial comment slide, about not knowing how to "read a chart", however, there is more here than meets the eye. I am not sure what that is! Let's hope it's positive and I'm wrong. What's the old adage... "G-d giveth and G-d taketh away?" LOL.

[TP-Money]

Still haven't received mine either. I do see that Scottrade sent me something in the mail regarding it, but I have not received the letter yet.

[serious38]

Today is the day of the Stock Dividend. haven't received mine today.

[willlbone]

Bear flag. Going down.

[brooklyn13]

Yes, there's probably no actual difference in buying now or next week. I tend to scale into positions, so what I really meant was that if I see it starting to move up, I'll be a buyer. The whole thing is a bit of a mystery, but I'm coming out far ahead because of the dividend payout, so I'm game.

[shmully]

I have to ask. If you think this stock is trading in an orderly fashion due to the dividend payout and are bullish on it, what's the difference if you get it for 7.5 cents or 8 cents (unless your buying millions of shares?) If you don't think it'll trade any lower than 7.5 cents, what difference does it make if it's pre or post dividend with the dividend payout only being less than a week away and your seemingly very positive spin on it? Sounds like there's a bit of hesitation and apprehension on your part. That's exactly how I'm feeling, which is what prompted my very first question.

[brooklyn13]

No, I think it will go back up, low for the past 3 years was .075. Even if I'm wrong, very limited downside.

[shmully]

Why will you be buying after the dividend payout? Do you think you will get this stock for less than 8 cents per share?

[brooklyn13]

Learn how to read a chart, do you even understand the dividend payout due next week? I'll be buying then.

[shanak10]

check out today's 13D/a filings.

[shmully]

Thanks for your input and the link to the article.

[shmully]

Down almost 90%. I think that boat has sailed. Let me know when you buy more.

[fatcat2]

Thanks for this pass info dated 7/12/2017